Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies
Investigation of the Gut Microbiota Evaluated by Metagenomic Next-Generation Sequencing (mNGS) in Acute Myeloid Leukemia Receiving Standard Intensive Chemotherapy or Bcl-2 Inhibitor-based Targeted Induction Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Suning Chen, Professor
- Phone Number: 8613814881746
- Email: chensuning@sina.com
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215000
- The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female, 65> =Age (years) >= 18;
- Newly diagnosed as AML patients according to World Health Organization (WHO) classification;
- Eastern Cooperative Oncology Group (ECOG) Performance status of 0,1,2;
- Patients will receive standard intensive chemotherapy (7+3) or bcl-2 inhibitor-based targeted therapy;
- Patients have not received prior therapy for AML (except hydroxycarbamide);
- Liver function: Total bilirubin lower than 3 upper limit of normal (ULN); Aspartate aminotransferase (AST) lower than 3 ULN; Alanine aminotransferase (ALT) lower than 3 ULN (except extramedullary infiltration of leukemia);
- Renal function with creatinine clearance rate (Ccr) higher than 30 ml/min;
- Patients who sign the informed consent must have the ability to understand and be willing to participate in the study and sign the informed consent.
Exclusion Criteria:
- Acute promyeloid leukemia;
- AML with central nervous system (CNS) infiltration;
- Any history of chronic intestinal affections (Crohn disease, inflammatory bowel disease, gluten intolerance) or gastrointestinal surgery;
- HIV infection, Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment;
- Severe and active infection that is difficult to control and cannot tolerate induction therapy;
- Female who are pregnant, breast feeding or childbearing potential without a negative urine pregnancy test at screen;
- Antibiotic exposure within 30 days before enrollment (carbapenems and/or tigecycline were not included, penicillin, cephalosporins and quinolones could be included)
- Patients reject to participate in the study;
- Patients with severe heart failure (grade 3-4) or patients deemed unsuitable for enrolment by the investigator.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Standard intensive chemotherapy
Patients with acute myeloid leukemia in this cohort will receive standard induction chemotherapy that combines seven days of cytarabine and three days of anthracycline (7+3 regimen).
|
blood and feces samples
|
|
Bcl-2 inhibitor-based targeted therapy
Patients with acute myeloid leukemia in this cohort will receive Bcl-2 inhibitor-based targeted therapy, such as combination of bcl-2 inhibitor plus decitabine/azacitidine with or without sorafenib.
|
blood and feces samples
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in gut microbiota composition in patients with acute myeloid leukemia before, during and after induction therapy
Time Frame: Day 0 i.e.: feces sampling is done at time of diagnosis before induction therapy
|
Sequencing DNA extracts from patients' feces to obtain the description of gut microbiota composition in those patients
|
Day 0 i.e.: feces sampling is done at time of diagnosis before induction therapy
|
|
Changes in metabolites composition of blood in patients with acute myeloid leukemia before, during and after induction therapy
Time Frame: Day 0 i.e.: blood sampling is done at time of diagnosis before induction therapy
|
Metabolomics performed on patients' blood to report the metabolites composition in those patients
|
Day 0 i.e.: blood sampling is done at time of diagnosis before induction therapy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in immune cells of blood in patients with acute myeloid leukemia before, during and after induction therapy
Time Frame: Day 0 i.e.: blood sampling is done at time of diagnosis before induction therapy
|
Immunomicin performed on patients' blood to report the composition of immune cells in those patients
|
Day 0 i.e.: blood sampling is done at time of diagnosis before induction therapy
|
|
Changes of gut permeability markers and microbial compounds of blood in patients with acute myeloid leukemia before, during and after induction therapy
Time Frame: Day 0 i.e.: blood sampling is done at time of diagnosis before induction therapy
|
ELISA (in pg/ml)
|
Day 0 i.e.: blood sampling is done at time of diagnosis before induction therapy
|
|
Infection rate during induction therapy
Time Frame: From date of first one cycle induction therapy start to the end of Cycle 1 (each cycle is 28 days) or death from any cause during Cycle 1 induction therapy.
|
Infection rate of patients with acute myeloid leukemia after two different induction therapy
|
From date of first one cycle induction therapy start to the end of Cycle 1 (each cycle is 28 days) or death from any cause during Cycle 1 induction therapy.
|
|
Rate of complete remission
Time Frame: From date of first one cycle induction therapy start to the end of Cycle 1 (each cycle is 28 days) or death from any cause during Cycle 1 induction therapy.
|
Complete remission after one cycle of induction therapy
|
From date of first one cycle induction therapy start to the end of Cycle 1 (each cycle is 28 days) or death from any cause during Cycle 1 induction therapy.
|
|
Changes in number of participants with treatment related-related adverse events as assessed by CTCAE v4.0
Time Frame: From date of first one cycle induction therapy start to the end of Cycle 1 (each cycle is 28 days) or death from any cause during Cycle 1 induction therapy.
|
CTCAE (common terminology criteria for adverse event version 4)
|
From date of first one cycle induction therapy start to the end of Cycle 1 (each cycle is 28 days) or death from any cause during Cycle 1 induction therapy.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Suning Chen, Professor, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AML-GutMicrobiota01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.